Clinical significance of serum miR-223, miR-25 and miR-375 in patients with esophageal squamous cell carcinoma
Clinical significance of serum miR-223, miR-25 and miR-375 in patients with esophageal squamous cell carcinoma
复制标题
DOI：
10.1007/s11033-013-2970-z
复制
发表时间：
2014-03-01
影响因子：
2.8
通讯作者：
Duan, Hongbing
中科院分区：
文献类型：
--
作者：
Wu, Chaohui;Li, Minjie;Duan, Hongbing
在许多癌症中发现了microRNA（miRNAs）表达谱的变化。本研究旨在探讨miR-25、miR-223和miR-375在食管鳞状细胞癌（ESCC）患者血清中的表达及其对生存结局的影响。我们采用定量逆转录聚合酶链反应检测了miR-25、miR-223和miR-375在20对ESCC癌组织和配对癌旁组织、94例健康志愿者和194例ESCC患者血清中的表达水平，并分析了血清miR-25、miR-223、miR-375的表达与ESCC的关系，以及miR-375和ESCC临床病理学参数以及存活率。miR-25和miR-223在食管鳞癌组织中的表达显著高于癌旁组织（P = 0.008和0.009），而miR-375在食管鳞癌组织中的表达显著低于癌旁组织（P = 0.006）。ESCC患者血清miR-25和miR-223的表达显著高于健康对照组，而血清miR-375的表达显著低于健康对照组（P = 0.007）。血清miR-25高表达与淋巴结转移显著相关（P = 0.01）。生存分析显示血清miR-223高表达和血清miR-375低表达与ESCC患者的生存不良相关[HR = 1.717，95%可信区间（CI）1.139-2.588，P = 0.01; HR = 1.750，95%CI 1.111-2.756，P = 0.016）。此外，高miR-223和低miR-375表达的患者比低miR-223和高miR-375表达的患者具有更高的死亡风险（HR = 3.599，95% CI 1.800-7.195，P = 2.92 x 10（-4））。总之，miR-25、miR-223和miR-375在ESCC组织和血清中异常表达。血清miR-223和miR-375是ESCC潜在的预后生物标志物。
Changes in the expression profiles of microRNAs (miRNAs) have been found in many cancers. The study was aimed to investigate the expression of miR-25, miR-223, and miR-375 in the serum of patients with esophageal squamous cell carcinoma (ESCC) and its effect on survival outcome. We examined the expression levels of miR-25, miR-223, and miR-375 in 20 pairs of ESCC cancer and matched paracancerous tissues, serum samples from 94 healthy volunteers and 194 patients with ESCC using quantitative reverse transcription polymerase chain reaction, and analyzed the relationship between expressions of serum miR-25, miR-223, and miR-375 and ESCC clinicopathological parameters as well as survival. Expressions of miR-25 and miR-223 were significantly increased in ESCC tissues compared with paracancerous tissues (P = 0.008 and 0.009, respectively), whereas the expression of miR-375 was significantly decreased in ESCC tissues compared with paracancerous tissues (P = 0.006). Expressions of serum miR-25 and miR-223 were significantly higher in ESCC patients than those in healthy controls, and, inversely, expression of serum miR-375 was significantly lower in ESCC patients than those in healthy controls (P = 0.007). High expression of serum miR-25 was significantly associated with lymph node metastasis (P = 0.01). Survival analysis showed that high expression of serum miR-223 and low expression of serum miR-375 were associated with poor survival in ESCC patients [hazard ratio (HR) = 1.717, 95 % confidence intervals (CI) 1.139-2.588, P = 0.01; HR = 1.750, 95 % CI 1.111-2.756, P = 0.016, respectively). Furthermore, Patients with high miR-223 and low miR-375 expression had higher risk of death than those with low miR-223 and high miR-375 expression (HR = 3.599, 95 % CI 1.800-7.195, P = 2.92 x 10(-4)). In conclusion, miR-25, miR-223, and miR-375 were abnormally expressed in ESCC tissues and sera. Serum miR-223 and miR-375 are potential prognostic biomarkers for ESCC.